The Expression Of CIDE-B And BCL-2in The Epithelial Ovarian Carcinoma

ObjectiveTo detect the protein expression of CIDE-B, BCL-2in the epithelial ovariancarcinoma. The relationship between the two proteins and the histology degree, thecriterion of FIGO, lymph node metastasis and the relevance of the two types of protein.The aim of this study is to discuss the action of CIDE-B, BCL-2in epithelial ovariancarcinoma, further to reveal the pathogenesis of the epithelial ovarian carcinoma, andprovide the basis for early diagnosis.Methods(1) Immunohistochemistry method was used to detect the expression of CIDE-B,BCL-2protein in80epithelial ovarian carcinoma,30benign epithelial ovarian tumortissues (of which15serous cystadenoma,11mucinous cystadenoma and4mixed tumor)and20normal ovarian tissue samples. Among80epithelial ovarian carcinoma were45serous cystadenocarcinoma,15mucinous cystadenocarcinoma,10endometrioidcarcinoma,6clear cell carcinoma,4transitional cell carcinoma; they were gradedaccording to histology degree: well-differentiated ovarain carcinoma,14samples,moderated differentiated ovarain carcinoma,29samples, and37samples were poorlydifferentiated; Clinical stage according the criterion of FIGO, Stage I,11samples, Stage II,13samples, Stage III,39samples, Stage IV,17samples;43cases were With regional lymphnode invasion group and37cases without regional lymph node invasion group.(2) Using the SPSS13.0to process the data，Chi一square test and spearmancorrelation analysis to statistieally analyze the data.Results(1)Immunohistochemistry results show that CIDE-B protein was located in theovarian cytoplasm and partial nucli, Which was brown granules. The BCL-2protein waslocated in the ovarian cytoplasm, Which was brown granules.(2)Expression of CIDE-B: For the expression of CIDE-B, there are15in of20 normal ovarian tissue samples show positive(75.0%);21of the30cases appear to bepositive in the benign epithelial ovarian tumor tissues (70.0%);35are seen to be positive inthe80cases of the epithelial ovarian carcinoma(43.8%). The positive expression rate ofCIDE-B protein in the epithelial ovarian carcinoma was showed lower than that in benignovarian tumor and normal ovarian tissue, Which was significantly different (χ2=10.028,P=0.007). The expression of CIDE-B protein in Stage III-IV was lower than that inStage I-II, which was significantly different (P<0.01). And well-differentiated was higherthan moderated and poorly differentiated, which was also significantly different (P<0.01).But there is no relationship with histological type and lymph node metastasis (P>0.05).(3)Expression of BCL-2: As to the BCL-2expression, there are5in the20cases ofnormal ovarian tissue samples appear to be positive(25.0%);9of the30cases appear to bepositive in the benign epithelial ovarian tumor tissues (35.0%);59are found to be positivein the80cases of epithelial ovarian carcinoma (73.8%). The positive expression rate ofBCL-2protein in the epithelial ovarian carcinoma was showed higher than that in benignovarian tumor and normal ovarian tissue, Which was significantly different (χ2=26.279,P=0.000). The expression of BCL-2protein in Stage III-IV was higher than that in StageI-II, which was significantly different (P<0.01). And well-differentiated was lower thanmoderated and poorly differentiated, which was also significantly different (P<0.01).Theexpression of BCL-2has nothing to do with lymph node metastasis (p>0.05).(4)There is negative correlation in the expression of CIDE-B, BCL-2in theepithelial ovarian carcinoma(r=-0.363, P<0.01).Conclusions1. The CIDE-B decreases significantly in the epithelial ovarian carcinoma.Furthermore, if there is lower tumor differentiation, there will be lower positiveexpression. This is possibly due to this-the CIDE-B losses may inhibit the cellapoptosis. Promoting the transforming of normal ovarian tissue to epithelial ovariancarcinoma.2. BCL-2increases significantly in the epithelial ovarian carcinoma. This mayinhibit the cell apoptosis, Promoting the possibility of ovarian carcinoma. BCL-2willdevelop along with the increase of pathological grading and clinical stages. Positive rate ofBCL-2will gradually increases, and with no relationship with lymph node metastasis.3. CIDE-B has a negative correlation with BCL-2. The loss of CIDE-B may promote the over-expression of BCL-2, so as to lead to the occurrence and development ofepithelial ovarian carcinoma.